Differences in the route of administration of vitamin K after excessive anticoagulant therapy: a randomized controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900023759

Enrollment

Unknown

Registered

2019-06-10

Start date

2019-06-15

Completion date

Unknown

Last updated

2019-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart valve disease, etc.

Interventions

oral group:Oral administration

intravenous group:Intravenous administration

subcutaneous injection group:Subcutaneous injection

intramuscular injection group:Intramuscular injection

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) patients taking warfarin; (2) patients whose INR is more than 3.5/4 during treatment; (3) patients who are able to monitor INR regularly and take follow-up; (4) patients informed and having agreed to sign the consent certificate.

Exclusion criteria

Exclusion criteria: (1) patients with the occurrence of important bleeding events or the need for emergency reversal of excessive anticoagulant; (2) patients known to be sensitive to vitamin K; (3) patients with glucose -6-phosphoric acid dehydrogenase deficiency; (4) patients with pregnancy or in breast milk period; (5)patients with severe hepatic insufficiency (Child-pugh C Class) or renal insufficiency (creatinine =2.0mg/dL).

Design outcomes

Primary

Measure	Time frame
Adverse event;	—

Secondary

Measure	Time frame
INR value after administration;	—

Countries

China

Contacts

Public ContactJinhua Zhang

Fujian Medical University Union Hospital

pollyzhang2006@126.com+86 13306912381

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026